tiprankstipranks
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug
Company Announcements

Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug

Pick the best stocks and maximize your portfolio:

An update from Stoke Therapeutics ( (STOK) ) is now available.

Stoke Therapeutics has secured FDA Breakthrough Therapy Designation for zorevunersen, an investigational treatment for Dravet syndrome, a severe genetic epilepsy. Clinical studies revealed promising results, showing significant seizure reduction and cognitive improvements in patients, positioning zorevunersen as a potential first-in-class disease-modifying therapy. The company is planning a global Phase 3 study to further assess zorevunersen’s efficacy. This development offers hope for improved treatment options for Dravet syndrome, a condition currently lacking effective disease-modifying therapies.

For a thorough assessment of STOK stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyStoke reports ‘substantial’ reductions in seizure frequency with zorevunersen
TheFlyStoke Therapeutics zorevunersen receives Breakthrough Therapy Designation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App